VivoSeq
Other

Women

2

Pipeline Programs↗

22

Active Trials↗

36

Companies Involved↗

Women is an early-stage landscape with 2 programs across 36 companies. The most active players are Eli Lilly, Sumitomo Pharma America, Inc., Pfizer. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

41/100

Mech. Concentration

100/100

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 1Pfizer logo

Pfizer

1 program

ApprovedBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Vibegron

Sumitomo Pharma America, Inc.

Phase 2
No programs
Phase 3
No programs
Approved1

Misoprostol

Pfizer

Analysis

Trial Status

236

clinical trials

Completed171 · 72%
Unknown status21 · 9%
Terminated15 · 6%
Recruiting9 · 4%
Not yet recruiting8 · 3%
Withdrawn7 · 3%
Other5 · 2%

Clinical Trials

Trial Activity

236 trials

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
Recruiting·LLoyola University·Phase 4·NCT05557279·40 enrolled
Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women
Recruiting·QQueen Mary University of London·Phase 1·NCT05597098·34 enrolled
Bicalutamide Therapy in Young Women With NAFLD and PCOS
Recruiting·UUniversity of California, San Francisco·Phase 1·NCT05979389·50 enrolled
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
Recruiting·UUBATEC·Phase 4·NCT06967753·50 enrolled
HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men
Recruiting·UUniversity of Zurich·Phase 4·NCT06498505·270 enrolled
L9LS in Women of Childbearing Potential in Mali
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07060508·290 enrolled
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
Recruiting·NNorthwest Women's and Children's Hospital, Xi'an, Shaanxi·N/A·NCT07185230·792 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Recruiting·Regeneron logoRegeneron·Phase 1/2·NCT04590326·612 enrolled
A Pilot Study Investigating the Effects of a Nutritional Supplement on Physiological and Metabolic Markers in 38-55-year-old Females
Recruiting·UUniversity of Southampton·Preclinical·NCT07615777·80 enrolled
BIYELA - Bexsero Immunisation in Young Women in Africa
Active, not recruiting·UUniversity of Washington·Phase 3·NCT06446752·1,100 enrolled
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Active, not recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT05358639·36 enrolled
The Women TDF-FTC Benchmark Study
Active, not recruiting·UUniversity of Washington·Phase 2·NCT05057858·72 enrolled
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT05450705·1,500 enrolled
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT07273474·12 enrolled
Menopausal HT for Women Living With HIV (HoT)
Not yet recruiting·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT06856174·105 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)